Correction: Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes (PLoS ONE (2014) 9, 4 (e96117) DOI:10.1371/journal.pone.0096117);Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Bai, Xiaoyan ^a,b,c,d   Li, Xiao ^d   Tian, Jianwei ^a,b,c,d   Zhou, Zhanmei ^a,b,c,d  

^a State Key Laboratory of Organic Geochemistry   (China)

^b State Key Laboratory of Organ Failure Research National Clinical Center of Kidney Disease   (China)

^c Guangdong Institute of Standardization   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ENDOSTATIN; GLUCOSE; PROTEIN KINASE B; VASCULOTROPIN A; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN II; FUSED HETEROCYCLIC RINGS; MEMBRANE PROTEIN; NEPHRIN; SMALL INTERFERING RNA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOWN REGULATION; DRUG BLOOD LEVEL; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE SILENCING; GLOMERULUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE; MALE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; URINARY EXCRETION; WESTERN BLOTTING; ACUTE KIDNEY INJURY; ANIMAL; CELL LINE; COMPLICATION; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANGIOGENESIS INHIBITORS; ANGIOTENSIN II; ANIMALS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; ENDOSTATINS; HETEROCYCLIC COMPOUNDS, 3-RING; MALE; MEMBRANE PROTEINS; MICE; PHOSPHORYLATION; PODOCYTES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899720136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103926     Document Type: Erratum

References (27)

1. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442. (Pubitemid 26102720)
2. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
3. Ferrara N (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814.
4. Thomas S, Vanuystel J, Gruden G, Rodriguez V, Burt D, et al. (2000) Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 11: 1236-1243. (Pubitemid 30416219)
5. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, et al. (2006) Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69: 1654-1661.
6. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, et al. (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239. (Pubitemid 29521855)
7. Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109 Suppl 2: S424-437. (Pubitemid 32577594)
8. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716. (Pubitemid 36278589)
9. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, et al. (2007) Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 104: 14448-14453. (Pubitemid 350003281)
10. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, et al. (2000) Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58: 2390-2399.
11. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, et al. (2006) Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69: 1986-1995. (Pubitemid 43924262)
12. Senthil D, Choudhury GG, McLaurin C, Kasinath BS (2003) Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 64: 468-479. (Pubitemid 36871918)
13. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000. (Pubitemid 32378340)
14. Tejada T, Catanuto P, Ijaz A, Santos JV, Xia X, et al. (2008) Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 73: 1385-1393. (Pubitemid 351770481)
15. Rane MJ, Song Y, Jin S, Barati MT, Wu R, et al. (2010) Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. Am J Physiol Renal Physiol 298: F49-61.
16. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, et al. (2002) A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638. (Pubitemid 34183927)
17. Verma R, Kovari I, Soofi A, Nihalani D, Patrie K, et al. (2006) Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 116: 1346-1359.
18. Schena FP, Gesualdo L (2005) Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16 Suppl 1: S30-33. (Pubitemid 41725079)
19. Satchell SC (2012) The glomerular endothelium emerges as a key player in diabetic nephropathy. Kidney Int 82: 949-951.
20. Nayak B, Xie P, Akagi S, Yang Q, Sun L, et al. (2005) Modulation of renalspecific oxidoreductase/myo-inositol oxygenase by high-glucose ambience. Proc Natl Acad Sci U S A 102: 17952-17957. (Pubitemid 41798483)
21. Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, et al. (2011) Podocyte vascular endothelial growth factor (Vegf(1)(6)(4)) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54: 1227-1241.
22. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, et al. (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656-1666.
23. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, et al. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343. (Pubitemid 26115364)
24. Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607.
25. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285. (Pubitemid 28015876)
26. Shichiri M, Hirata Y (2001) Antiangiogenesis signals by endostatin. FASEB J 15: 1044-1053. (Pubitemid 32290793)
27. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, et al. (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17: 3093-3104. (Pubitemid 44707769)